Yang Wenya, Cintina Inna, Hoerger Thomas, Neuwahl Simon J, Shao Hui, Laxy Michael, Zhang Ping
The Lewin Group, 3160 Fairview Park Drive #600, Falls Church, VA 22042, USA.
RTI International, 3040 East Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC 27709-2194, USA.
J Diabetes Complications. 2020 Dec;34(12):107735. doi: 10.1016/j.jdiacomp.2020.107735. Epub 2020 Sep 6.
To estimate the cost of diabetes complications in the United States (U.S.).
We constructed longitudinal panel data using one of the largest claims databases in the U.S. for privately insured Type 1 (T1DM) and type 2 (T2DM) diabetes patients with a follow-up time of one to ten years. Complication costs were estimated both in years of the first occurrence and in subsequent years, using individual fixed-effects models. All costs were in 2016 dollars.
47,166 people with T1DM and 608,237 with T2DM were included in our study. Aside from organ transplants, which were rare, the estimated average costs for the top three most costly conditions in the first vs. subsequent years were: end stage renal disease ($73,534 vs. $97,431 for T1DM; $94,231 vs. $98,981 for T2DM), congestive heart failure ($41,681 vs. $14,855 for T1DM; $31,202 vs. $7062 for T2DM), and myocardial infarction ($40,899 vs. $9496 for T1DM; $45,251 vs. $8572 for T2DM). For both diabetes types, retinopathy and neuropathy tend to have the lowest cost estimates.
Our study provides the latest and most comprehensive cost estimates for a broad set of diabetes complications needed to evaluate the long-term cost-effectiveness of interventions for preventing and managing diabetes.
评估美国糖尿病并发症的成本。
我们利用美国最大的理赔数据库之一构建纵向面板数据，该数据库涵盖了1型糖尿病（T1DM）和2型糖尿病（T2DM）的私人保险患者，随访时间为1至10年。使用个体固定效应模型，对首次发生并发症的年份以及随后年份的并发症成本进行了估计。所有成本均以2016年美元计算。
我们的研究纳入了47166名T1DM患者和608237名T2DM患者。除了罕见的器官移植外，在第一年与随后几年中，三种成本最高病症的估计平均成本分别为：终末期肾病（T1DM为73534美元对97431美元；T2DM为94231美元对98981美元）、充血性心力衰竭（T1DM为41681美元对14855美元；T2DM为31202美元对7062美元）以及心肌梗死（T1DM为40899美元对9496美元；T2DM为45251美元对8572美元）。对于这两种糖尿病类型，视网膜病变和神经病变的成本估计往往最低。
我们的研究为广泛的糖尿病并发症提供了最新、最全面的成本估计，这些估计对于评估预防和管理糖尿病干预措施的长期成本效益是必要的。
